Abstracts tagged "Disease Activity"

Abstract Number: 0421 • ACR Convergence 2024
The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study
Katya Meridor¹, Shimi Barda², sara Pel³, sharon Nevo², Julia Berman², daphna paran⁴, Ori Elkayam⁵ and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel-Aviv Medical Center, Tel-Aviv, Israel, ³Tel-Aviv Medical Center, Petah-Tikva, Israel, ⁴Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 0571 • ACR Convergence 2024
Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
Sabrina Hamroun¹, Laure Gossec², Serge Perrot³, Maxime Dougados⁴ and Anna Molto⁵, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Sorbonne Université, Paris, France, ³Paris Dauphine University, Paris, France, ⁴Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁵Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: There are several tools for assessing disease activity in spondyloarthritis (SpA). The literature reveals gender differences, with unfavorable Patient Reported Outcomes in women compared…
Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Victoria Werth¹, Joseph F. Merola², Qianyun Li³, Weihong Yang³ and Catherine Barbey⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²UT Southwestern Medical Center, Dallas, TX, ³Biogen, Cambridge, MA, ⁴Biogen, Baar, Switzerland
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…
Abstract Number: 1113 • ACR Convergence 2024
2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response
Young Min Cho¹, Alejandro Quintero Villegas², Matt Means³, Zanos Theodoros², Lara El Khoury⁴ and Galina Marder³, ¹Northwell, Glen Cove, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Northwell, Manhasset, NY, ⁴Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: IgG4-RD presents various clinical manifestations, making it challenging to assess treatment responses. B-cell depletion agents such as Rituximab (RTX) are used in refractory cases.…
Abstract Number: 1350 • ACR Convergence 2024
Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis
Tulsi Joishy, Sheau-Chiann Chen, Qiong Wu and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting the joints that is associated with increased cardiovascular risk. Environmental factors play a crucial role…
Abstract Number: 1429 • ACR Convergence 2024
Association of Bone Erosion and Microarchitecture with Disease Activity and Damage in Sjögren’s Disease
Andre Franco¹, Igor Murai², Thomas Yang², Valeria Caparbo³, Virginia Bonoldi², Diogo Domiciano¹, Lissiane Guedes², Sandra Pasoto¹, Camille Figueiredo³ and Rosa M R Pereira³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina da USP, São Paulo, SP, Brazil, ³Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, SP, Brazil
Background/Purpose: Sjögren's disease (SjD) is a chronic multisystem autoimmune condition characterized by sicca syndrome and inflammatory arthralgia, more common in women. Bone involvement can result…
Abstract Number: 1722 • ACR Convergence 2024
Machine Learning-based Risk Stratification Tool to Predict Early Flare for Rheumatic and Musculoskeletal Diseases
Pradip Moon¹, Weizi Li¹, Antoni Chan² and Eghosa Bazuaye², ¹University of Reading, Reading, United Kingdom, ²Royal Berkshire NHS Foundation Trust, Reading, United Kingdom
Background/Purpose: Rheumatic and musculoskeletal diseases (RMD) affect up to one-third of the UK population and are the number one cause of disability and one of…
Abstract Number: 2071 • ACR Convergence 2024
Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset
praggya yaadav¹, Maria Rosa Pellico², Anne-Marie Russell³, Aviya Lanis⁴, Elena Nikiphorou⁵, Ioannis Parodis⁶, Sreoshy Saha⁷, Manali Sarkar⁸, Jasmine Parihar⁹, Laura Andreoli¹⁰, Vikas Agarwal¹¹ and Latika Gupta¹², and COVAD Steering Committee, COVAD Study Group, ¹Maharashtra Institute of Medical Sciences and Research, Latur, Aurangabad, India, ²University of Milan, Milan, Italy, ³Birmingham Regional Interstitial Lung Disease Service, University Hospitals Birmingham NHS Trust and Faculty of Life Sciences, University of Exeter, Exeter, UK, Birmingham, United Kingdom, ⁴Seattle Children's Hospital, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁷Mymensingh Medical College, Mymensingh, Bangladesh, ⁸MGM Medical College, Navi Mumbai, Maharashtra, India, ⁹All India Institute of Medical Science, New Delhi, Delhi, India, ¹⁰University of Brescia, Brescia, Italy, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹²Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
Background/Purpose: Self-efficacy is crucial for chronic disease management. Given the increasing prevalence of chronic diseases, encouraging patients to actively manage their disease may be an…
Abstract Number: 2362 • ACR Convergence 2024
Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Lianne S Gensler¹, Helena Marzo-Ortega², Vanessa Taieb³, Diana Voiniciuc⁴, Alexander Marten⁵, George Stojan⁶, Mindy Kim⁶ and Martin Rudwaleit⁷, ¹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³UCB Pharma, Colombes, France, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Atlanta, GA, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ has demonstrated sustained efficacy and safety to Week…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 0432 • ACR Convergence 2024
Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study
Marion couderc¹, celine lambert², sabrina hamroun³, denis gallot⁴, Nathalie Costedoat-chalumeau⁵, Laure Gossec⁶, Gaëlle Guettrot-Imbert⁷, Veronique LE GUERN⁷, Christophe Richez⁸, MArtin Soubrier⁹ and Anna Molto¹⁰, ¹CHU de Clermont-Ferrand, Clermont-Ferrand, ²chu clermont ferrand, clermont ferrand, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Department of Obstetrics, CHU Clermont-ferrand, Clermont-Ferrand, Auvergne, France, ⁵University Paris Cité, Paris, France, ⁶Sorbonne Université, Paris, France, ⁷Cochin Hospital, Paris, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁰Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim…
Abstract Number: 0578 • ACR Convergence 2024
Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
Muhammad Saeed¹, HIna Ahmed² and Aziza Ahmed³, and Arthritis Carte Foundation Faculty, ¹Central Park Medical College, Arthritis Care Foundation, Lahore, Pakistan, ²Central Park Medical College, Lahore, Pakistan, ³Rashid Latif Medical College, Lahore, Pakistan
Background/Purpose: In patients with Axial Spondyloarthritis (axSpA) there has been wide variability in terms of gender regarding disease characteristics as well as outcomes across different…
Abstract Number: 0711 • ACR Convergence 2024
Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
Natania Field¹, Monica Yang², Niket Gupta¹, Maxwell Shramuk¹, Lutfiyya Muhammad¹, Vivien Goh¹, Monica Espinoza³, Yiwei Yuan³, Rezvan Parvizi³, Kathleen Aren⁴, Mary Carns⁴, Isaac Goldberg⁵, Lorinda Chung⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield³ and Monique Hinchcliff⁹, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²UCSF, San Francisco, CA, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Wayne State University School of Medicine, Detroit, MI, ⁶Stanford University, Woodside, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸UTHealth Houston Division of Rheumatology, Houston, TX, ⁹Yale School of Medicine, Westport, CT
Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…
Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 1351 • ACR Convergence 2024
Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements
Woo-Joong KIM¹, Chanseok PARK², Seungmo KOO², Jae-Young CHEONG² and Jiho KIM², ¹Chung-Ang University Hospital, Seoul, Korea, Seoul, Republic of Korea, ²Hongik University, Seoul, Korea, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires regular monitoring to prevent joint damage and systemic complications. However, the shortage of trained…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].